8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
May 1, 2026·SEC
Material company update
Feb 12, 2026·SEC
AVITA Medical, Inc.(RCEL)Earnings, Financials & Key Ratios
RCEL•NASDAQ
Price updated Jun 19, 2026
AboutAVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.Show more
- Revenue$72M+11.5%
- EBITDA-$40M+28.6%
- Net Income-$49M+21.4%
- EPS (Diluted)-1.74+27.2%
- Gross Margin82.13%-4.3%
- EBITDA Margin-55.28%+36.0%
- Operating Margin-58.56%+33.5%
- Net Margin-67.85%+29.5%
RCEL Key Insights
AVITA Medical, Inc. (RCEL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 19.6%
- ✓Efficient asset utilization: 1.3x turnover
✗Weaknesses
- ✗Profits declining 12.8% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when RCEL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RCEL Price & Volume
AVITA Medical, Inc. (RCEL) stock price & volume — 10-year historical chart
Loading chart...
RCEL Growth Metrics
AVITA Medical, Inc. (RCEL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years53.25%
5 Years19.63%
3 Years27.66%
TTM0.96%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM20.52%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM28.31%
Return on Capital
10 Years-93.42%
5 Years-65.11%
3 Years-91.65%
Last Year-157.45%
RCEL Recent Earnings
AVITA Medical, Inc. (RCEL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (17%)●Beat Revenue 3/12 qtrs (25%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$0.35+0.0%
$0.35
Rev
$19M+5.2%
$18M
Q1 2026
Feb 12, 2026Metric
Actual
Est
EPS
$0.38-4.3%
$0.36
Rev
$17M-2.3%
$18M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.46-7.0%
$0.43
Rev
$17M-36.5%
$27M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.38-46.2%
$0.26
Rev
$12M-70.1%
$40M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.35vs $0.35+0.0% | $19Mvs $18M+5.2% |
| Q1 2026 | Feb 12, 2026 | $0.38vs $0.36-4.3% | $17Mvs $18M-2.3% |
| Q4 2025 | Nov 6, 2025 | $0.46vs $0.43-7.0% | $17Mvs $27M-36.5% |
| Q3 2025 | Aug 7, 2025 | $0.38vs $0.26-46.2% | $12Mvs $40M-70.1% |
Based on last 12 quarters of dataView full earnings history →
RCEL Peer Comparison
AVITA Medical, Inc. (RCEL) competitors in Aesthetics, dermatology, and wound care — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 XTNT | 61.8M | 0.44 | 14.69 | 14.21% | 1.5% | 3.68% | 0.56 | |
 TELA | 36.85M | 0.82 | -0.99 | 15.84% | -49.3% | -13.44% | 8.82 | |
 MDXG | 545.24M | 3.67 | 11.47 | 19.99% | 7.88% | 12.86% | 0.09 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 APYX | 172.1M | 4.11 | -15.22 | 9.86% | -16.4% | -88.47% | 2.65 | |
 ANGO | 505.13M | 12.15 | -14.64 | -3.76% | -9.02% | -15.71% | ||
 SYK | 117.88B | 307.80 | 36.64 | 11.16% | 12.92% | 15.04% | 0.66 | |
 BSX | 67.31B | 45.29 | 23.35 | 19.87% | 14.4% | 12.4% | 0.51 |
Compare RCEL vs Peers
AVITA Medical, Inc. (RCEL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RCEL Income Statement
AVITA Medical, Inc. (RCEL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.26M | 5.47M | 14.26M | 29.23M | 33.02M | 34.42M | 50.14M | 64.25M | 71.61M | 72.35M |
Revenue Growth % | 6.31% | 336.12% | 160.56% | 104.95% | 12.98% | 4.23% | 45.68% | 28.14% | 11.45% | 0.96% |
Cost of Goods Sold | 737.7K | 1.27M | 2.97M | 5.95M | 6.1M | 6.04M | 7.78M | 9.09M | 12.79M | 13.48M |
COGS % of Revenue | 58.77% | 23.22% | 20.84% | 20.35% | 18.48% | 17.55% | 15.52% | 14.15% | 17.87% | - |
Gross Profit | 517.47K▲ 0% | 4.2M▲ 712.2% | 11.29M▲ 168.6% | 23.28M▲ 106.2% | 26.92M▲ 15.6% | 28.38M▲ 5.4% | 42.36M▲ 49.3% | 55.16M▲ 30.2% | 58.82M▲ 6.6% | 58.86M▲ 0% |
Gross Margin % | 41.23% | 76.78% | 79.16% | 79.65% | 81.52% | 82.45% | 84.48% | 85.85% | 82.13% | 81.36% |
Gross Profit Growth % | -23.34% | 712.22% | 168.62% | 106.23% | 15.63% | 5.42% | 49.27% | 30.2% | 6.63% | - |
Operating Expenses | 19.15M | 29.73M | 53.97M | 49.82M | 52.04M | 55.88M | 85.02M | 111.75M | 100.75M | 98.38M |
OpEx % of Revenue | 1525.4% | 543.13% | 378.38% | 170.44% | 157.57% | 162.36% | 169.55% | 173.93% | 140.69% | - |
Selling, General & Admin | 21.21M | 27.65M | 48.73M | 37.06M | 37.21M | 45.24M | 65.63M | 91.39M | 79.91M | 78.19M |
SG&A % of Revenue | 1690.1% | 505.08% | 341.66% | 126.78% | 112.68% | 131.44% | 130.88% | 142.24% | 111.59% | - |
Research & Development | 8.45M | 8M | 9.16M | 14.82M | 15.67M | 13.86M | 20.82M | 20.36M | 20.84M | 20.18M |
R&D % of Revenue | 673.52% | 146.22% | 64.25% | 50.69% | 47.45% | 40.26% | 41.52% | 31.69% | 29.1% | - |
Other Operating Expenses | 0 | -5.92M | -3.93M | -2.06M | -843K | -3.21M | -1.43M | 0 | 0 | 0 |
Operating Income | -18.7M▲ 0% | -25.53M▼ 36.5% | -42.68M▼ 67.2% | -26.54M▲ 37.8% | -25.12M▲ 5.4% | -27.5M▼ 9.5% | -42.66M▼ 55.1% | -56.59M▼ 32.7% | -41.93M▲ 25.9% | -39.51M▲ 0% |
Operating Margin % | -1489.88% | -466.35% | -299.23% | -90.79% | -76.06% | -79.91% | -85.07% | -88.08% | -58.56% | -54.61% |
Operating Income Growth % | -47.59% | -36.51% | -67.19% | 37.81% | 5.36% | -9.5% | -55.08% | -32.68% | 25.9% | - |
EBITDA | -18.6M | -25.59M | -42.21M | -25.82M | -24.45M | -26.94M | -42.02M | -55.47M | -39.59M | -37.06M |
EBITDA Margin % | -1481.48% | -467.5% | -295.97% | -88.34% | -74.02% | -78.26% | -83.81% | -86.33% | -55.28% | -51.22% |
EBITDA Growth % | -48.4% | -37.62% | -64.96% | 38.82% | 5.34% | -10.19% | -56% | -31.99% | 28.63% | 25.54% |
D&A (Non-Cash Add-back) | 105.45K | -63K | 465K | 715K | 673K | 568K | 632K | 1.13M | 2.35M | 2.45M |
EBIT | -18.7M | -25.2M | -41.99M | -26.52M | -25.08M | -26.61M | -34.17M | -56.43M | -41.93M | -39.78M |
Net Interest Income | 28.37K | -27K | 47.82K | -33K | -29K | 23.5K | -1.14M | -5.36M | -5M | -5.51M |
Interest Income | 28.37K | 0 | 47.82K | 0 | 0 | 23.5K | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 27K | 0 | 33K | 29K | 16K | 1.14M | 5.36M | 5M | 5.51M |
Other Income/Expense | 43.24K | 305K | 653K | -5K | 18K | 876K | 7.34M | -5.2M | -6.64M | -5.84M |
Pretax Income | -18.66M▲ 0% | -25.22M▼ 35.2% | -42.03M▼ 66.6% | -26.55M▲ 36.8% | -25.1M▲ 5.4% | -26.63M▼ 6.1% | -35.31M▼ 32.6% | -61.79M▼ 75.0% | -48.58M▲ 21.4% | -45.35M▲ 0% |
Pretax Margin % | -1486.44% | -460.78% | -294.65% | -90.81% | -76% | -77.36% | -70.43% | -96.17% | -67.83% | -62.68% |
Income Tax | 1.45M | -121K | 4K | 38K | 42K | 36K | 66K | 54K | 11K | -9K |
Effective Tax Rate % | -7.78% | 0.48% | -0.01% | -0.14% | -0.17% | -0.14% | -0.19% | -0.09% | -0.02% | 0.02% |
Net Income | -17.21M▲ 0% | -25.1M▼ 45.9% | -42.03M▼ 67.4% | -26.58M▲ 36.8% | -25.14M▲ 5.4% | -26.66M▼ 6.1% | -35.38M▼ 32.7% | -61.84M▼ 74.8% | -48.59M▲ 21.4% | -45.34M▲ 0% |
Net Margin % | -1370.83% | -458.57% | -294.68% | -90.94% | -76.13% | -77.47% | -70.56% | -96.26% | -67.85% | -62.67% |
Net Income Growth % | -49.48% | -45.89% | -67.44% | 36.75% | 5.42% | -6.06% | -32.69% | -74.8% | 21.44% | 20.52% |
Net Income (Continuing) | - | -25.1M | -42.03M | -26.58M | -25.14M | -26.66M | -35.38M | -61.84M | -48.59M | -45.34M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.85▲ 0% | -1.12▲ 39.5% | -3.00▼ 167.9% | -1.17▲ 61.0% | -1.03▲ 12.0% | -1.07▼ 3.9% | -1.40▼ 30.8% | -2.39▼ 70.7% | -1.74▲ 27.2% | -0.15▲ 0% |
EPS Growth % | -7.56% | 39.46% | -167.86% | 61% | 11.97% | -3.88% | -30.84% | -70.71% | 27.2% | 28.31% |
EPS (Basic) | -1.84 | -1.12 | -3.00 | -1.17 | -1.03 | -1.07 | -1.40 | -2.39 | -1.74 | - |
Diluted Shares Outstanding | 9.33M | 22.33M | 20.29M | 20.29M | 24.36M | 25M | 25.33M | 25.88M | 27.86M | 305.41M |
Basic Shares Outstanding | 9.3M | 22.33M | 20.29M | 20.29M | 24.36M | 25M | 25.33M | 25.88M | 27.86M | 305.41M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
RCEL Balance Sheet
AVITA Medical, Inc. (RCEL) balance sheet — assets, liabilities & shareholders' equity
| Metric | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 22.26M | 24.13M | 78.39M | 121.33M | 92.13M | 87.46M | 104.01M | 57M | 35.49M | 31.65M |
Cash & Short-Term Investments | 14.82M | 20.17M | 73.64M | 110.75M | 85.16M | 79.34M | 89.06M | 35.88M | 18.18M | 14.26M |
Cash Only | 14.82M | 20.17M | 73.64M | 110.75M | 55.51M | 18.16M | 22.12M | 14.05M | 10.24M | 8.31M |
Short-Term Investments | 0 | 0 | 0 | 0 | 29.65M | 61.18M | 66.94M | 21.84M | 7.94M | 5.95M |
Accounts Receivable | 239.81K | 1.91M | 2.51M | 7.88M | 3.43M | 4.96M | 7.92M | 11.96M | 9.09M | 9.88M |
Days Sales Outstanding | 69.74 | 127.42 | 64.16 | 98.43 | 37.87 | 52.6 | 57.66 | 67.96 | 46.31 | 50.06 |
Inventory | 1.16M | 742K | 1.13M | 1.65M | 2.13M | 2.13M | 5.6M | 7.27M | 6.93M | 6.12M |
Days Inventory Outstanding | 571.5 | 213.08 | 138.12 | 101.05 | 127.49 | 128.39 | 262.54 | 291.75 | 197.59 | 188.26 |
Other Current Assets | 6.05M | 200K | 201K | 201K | 290K | 0 | 18K | 1.88M | 1.29M | 1.38M |
Total Non-Current Assets | 742.09K | 1.66M | 4.08M | 4.17M | 23.88M | 10.81M | 7.63M | 22.71M | 20.9M | 19.9M |
Property, Plant & Equipment | 742.09K | 1.31M | 3.71M | 2.94M | 2.81M | 2.05M | 4.32M | 13.59M | 11.53M | 10.88M |
Fixed Asset Turnover | 1.69x | 4.18x | 3.84x | 9.95x | 11.77x | 16.78x | 11.62x | 4.73x | 6.21x | 6.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 225K | 364K | 472K | 443K | 465K | 487K | 5.57M | 5.64M | 5.44M |
Long-Term Investments | 0 | 0 | 0 | 0 | 19.69M | 6.93M | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 125K | 1K | 761K | 942K | 1.36M | 2.83M | 3.55M | 3.73M | 3.58M |
Total Assets | 23M▲ 0% | 25.78M▲ 12.1% | 82.46M▲ 219.8% | 125.5M▲ 52.2% | 116.02M▼ 7.6% | 98.26M▼ 15.3% | 111.64M▲ 13.6% | 79.71M▼ 28.6% | 56.39M▼ 29.3% | 51.54M▲ 0% |
Asset Turnover | 0.05x | 0.21x | 0.17x | 0.23x | 0.28x | 0.35x | 0.45x | 0.81x | 1.27x | 1.26x |
Asset Growth % | 199.97% | 12.1% | 219.82% | 52.19% | -7.56% | -15.3% | 13.61% | -28.6% | -29.25% | -110.33% |
Total Current Liabilities | 3.88M | 4.48M | 7.71M | 7.39M | 9.15M | 10.69M | 13.2M | 20.16M | 62.68M | 66.67M |
Accounts Payable | 271.73K | 1.92M | 4.33M | 3.12M | 2.71M | 3M | 3.79M | 6.29M | 8.96M | 0 |
Days Payables Outstanding | 134.45 | 550.23 | 531.97 | 191.43 | 161.93 | 181.38 | 177.95 | 252.62 | 255.59 | 164.67 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 42.98M | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 33K | 0 | 0 | 0 |
Other Current Liabilities | 3.61M | 438K | 560K | 949K | 355K | 456K | 506K | 2.51M | 9.8M | 66.67M |
Current Ratio | 5.74x | 5.38x | 10.17x | 16.42x | 10.07x | 8.18x | 7.88x | 2.83x | 0.57x | 0.47x |
Quick Ratio | 5.44x | 5.22x | 10.02x | 16.20x | 9.84x | 7.98x | 7.46x | 2.47x | 0.46x | 0.38x |
Cash Conversion Cycle | 506.79 | -209.72 | -329.7 | 8.05 | 3.42 | -0.39 | 142.25 | 107.09 | -11.69 | 73.65 |
Total Non-Current Liabilities | 134.25K | 471K | 2.35M | 2.46M | 2.25M | 2.83M | 49.38M | 55.05M | 10.37M | 8.04M |
Long-Term Debt | 134.25K | 0 | 0 | 0 | 0 | 0 | 39.81M | 42.24M | 0 | 1.98M |
Capital Lease Obligations | 0 | 0 | 1.92M | 878K | 918K | 306K | 1.7M | 2.84M | 2.13M | 6.83M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 42.46K | 0 | 503K | 1.33M | 1.83M | 7.51M | 9.64M | 7.94M | 6.06M |
Total Liabilities | 4.01M | 4.95M | 10.06M | 9.85M | 11.39M | 13.52M | 62.58M | 75.21M | 73.04M | 74.71M |
Total Debt | 134.25K | 0 | 1.92M | 878K | 1.64M | 918K | 42.41M | 45.98M | 46.05M | 1.98M |
Net Debt | -14.68M | -20.17M | -71.72M | -109.87M | -53.87M | -17.25M | 20.29M | 31.93M | 35.8M | -6.33M |
Debt / Equity | 0.01x | - | 0.03x | 0.01x | 0.02x | 0.01x | 0.86x | 10.22x | - | -0.09x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.05x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.17x |
Interest Coverage | - | -933.19x | - | -803.73x | -864.69x | -1663.31x | -29.90x | -10.53x | -8.38x | -7.22x |
Total Equity | 18.99M▲ 0% | 20.83M▲ 9.7% | 72.4M▲ 247.5% | 115.66M▲ 59.7% | 104.62M▼ 9.5% | 84.74M▼ 19.0% | 49.06M▼ 42.1% | 4.5M▼ 90.8% | -16.65M▼ 470.1% | -23.17M▲ 0% |
Equity Growth % | 270.71% | 9.72% | 247.55% | 59.74% | -9.54% | -19.01% | -42.11% | -90.83% | -470.08% | -1185.31% |
Book Value per Share | 2.04 | 0.93 | 3.57 | 5.70 | 4.30 | 3.39 | 1.94 | 0.17 | -0.60 | -0.08 |
Total Shareholders' Equity | 18.99M | 20.83M | 72.4M | 115.66M | 104.62M | 84.74M | 49.06M | 4.5M | -16.65M | -23.17M |
Common Stock | 162.69M | 3K | 3K | 3K | 3K | 3K | 3K | 3K | -1.29M | -632K |
Retained Earnings | -148.49M | -152.83M | -194.91M | -221.5M | -235.92M | -262.59M | -297.97M | -359.81M | -408.4M | -419.01M |
Treasury Stock | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 4.79M | 8.18M | 8.15M | 8.26M | 8.06M | 7.63M | -1.89M | -1.94M | -1.37M | 648K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RCEL Cash Flow Statement
AVITA Medical, Inc. (RCEL) cash flow — operating, investing & free cash flow history
| Metric | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -9.54M | -19.25M | -22.75M | -25.9M | -18.04M | -19.09M | -38.01M | -48.94M | -31.2M | -30.96M |
Operating CF Margin % | -760.03% | -351.66% | -159.48% | -88.61% | -54.62% | -55.46% | -75.81% | -76.17% | -43.56% | - |
Operating CF Growth % | -45.07% | -101.79% | -18.17% | -13.87% | 30.36% | -5.84% | -99.11% | -28.75% | 36.26% | 82.62% |
Net Income | -9.37M | -25.1M | -42.03M | -26.58M | -25.14M | -26.66M | -35.38M | -61.84M | -48.59M | -45.34M |
Depreciation & Amortization | 80.97K | 269K | 465K | 715K | 969K | 568K | 632K | 1.13M | 2.04M | 2.15M |
Stock-Based Compensation | 0 | 1.95M | 16.59M | 5.66M | 6.33M | 7M | 8.38M | 13.5M | 9.52M | 6.83M |
Deferred Taxes | 0 | -129K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 365.1K | 494K | 895K | 1.66M | 1.53M | 1.21M | -5.07M | 2.96M | 2.4M | 4.44M |
Working Capital Changes | -611.68K | 3.27M | 1.33M | -7.36M | -1.73M | -1.2M | -6.57M | -4.68M | 3.44M | 967K |
Change in Receivables | -1.39M | 1.97M | -582K | -4.98M | -1.19M | -985K | -3.3M | -4.17M | 3.63M | 3.09M |
Change in Inventory | -69.19K | 17K | -468K | -745K | -144K | -371K | -3.69M | -2.16M | -468K | 1.72M |
Change in Payables | 0 | 69K | 2.31M | -1.33M | 0 | 282K | 809K | 340K | 2.75M | -1.37M |
Cash from Investing | -268.67K | 0 | -847K | -1.17M | -50.21M | -19.33M | 1.61M | 37.36M | 12.45M | 3.73M |
Capital Expenditures | -268.67K | 0 | -590K | -894K | -487K | -452K | -1.38M | -9.17M | 0 | 199K |
CapEx % of Revenue | 21.41% | - | 4.14% | 3.06% | 1.47% | 1.31% | 2.75% | 14.27% | 1.4% | 0.28% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | -257K | -280K | -49.72M | -73K | -66K | -162K | -1.74M | -1.73M |
Cash from Financing | 15.67M | 0 | 77.06M | 64.05M | 64.06M | 900K | 40.37M | 3.51M | 14.94M | 20.67M |
Debt Issued (Net) | -44.9K | 0 | -42K | -11K | -11K | 0 | 38.76M | 0 | 0 | 6.1M |
Equity Issued (Net) | 16.78M | 0 | 81.7M | 69.11M | 0 | 0 | 0 | 0 | 14.14M | 14.03M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -1.06M | 0 | -4.6M | -5.05M | 64.08M | 900K | 1.61M | 3.51M | 795K | 540.09K |
Net Change in Cash | 5.94M▲ 0% | 0▼ 100.0% | 53.47M▲ 0% | 37.11M▼ 30.6% | 37.11M▲ 0.0% | -37.55M▼ 201.2% | 3.95M▲ 110.5% | -8.07M▼ 304.0% | -3.81M▲ 52.8% | -6.56M▲ 0% |
Free Cash Flow | -9.81M▲ 0% | 0▲ 100.0% | -23.59M▲ 0% | -27.07M▼ 14.8% | -18.52M▲ 31.6% | -19.61M▼ 5.9% | -39.46M▼ 101.2% | -58.27M▼ 47.7% | -32.2M▲ 44.7% | -30.74M▲ 0% |
FCF Margin % | -781.43% | - | -165.42% | -92.62% | -56.09% | -56.99% | -78.69% | -90.69% | -44.97% | -42.49% |
FCF Growth % | - | 100% | - | -14.75% | 31.58% | -5.89% | -101.16% | -47.68% | 44.74% | 34.2% |
FCF per Share | -1.05 | - | -1.16 | -1.33 | -0.76 | -0.78 | -1.56 | -2.25 | -1.16 | -0.10 |
FCF Conversion (FCF/Net Income) | 0.55x | 0.77x | 0.54x | 0.97x | 0.72x | 0.72x | 1.07x | 0.79x | 0.64x | 0.68x |
Interest Paid | - | 27K | 42K | 3K | 29K | 15K | 1.14M | 5.36M | 0 | -1.23M |
Taxes Paid | - | 0 | 0 | 42K | 0 | 17K | 44K | 41K | 0 | 0 |
RCEL Key Ratios
AVITA Medical, Inc. (RCEL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -142.74% | -126.08% | -90.16% | -28.27% | -22.83% | -28.16% | -52.89% | -230.96% | - | 305.45% |
Return on Invested Capital (ROIC) | -497.63% | -771.47% | -4788.22% | -615.68% | -66.64% | -34.89% | -46.76% | -80.25% | -113.15% | -372.45% |
Gross Margin | 41.23% | 76.78% | 79.16% | 79.65% | 81.52% | 82.45% | 84.48% | 85.85% | 82.13% | 81.36% |
Net Margin | -1370.83% | -458.57% | -294.68% | -90.94% | -76.13% | -77.47% | -70.56% | -96.26% | -67.85% | -62.67% |
Debt / Equity | 0.01x | - | 0.03x | 0.01x | 0.02x | 0.01x | 0.86x | 10.22x | - | -0.09x |
Interest Coverage | - | -933.19x | - | -803.73x | -864.69x | -1663.31x | -29.90x | -10.53x | -8.38x | -7.22x |
FCF Conversion | 0.55x | 0.77x | 0.54x | 0.97x | 0.72x | 0.72x | 1.07x | 0.79x | 0.64x | 0.68x |
Revenue Growth | 6.31% | 336.12% | 160.56% | 104.95% | 12.98% | 4.23% | 45.68% | 28.14% | 11.45% | 0.96% |
Related:RCEL Dividend History·RCEL Revenue History·RCEL Price History·RCEL P/E History·RCEL Financial Ratios·RCEL Institutional Holders
RCEL SEC Filings & Documents
AVITA Medical, Inc. (RCEL) SEC filings — annual & quarterly reports (10-K, 10-Q)
RCEL Frequently Asked Questions
AVITA Medical, Inc. (RCEL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
AVITA Medical, Inc. (RCEL) reported $72.3M in revenue for fiscal year 2025.
AVITA Medical, Inc. (RCEL) grew revenue by 11.5% over the past year. This is steady growth.
AVITA Medical, Inc. (RCEL) reported a net loss of $45.3M for fiscal year 2025.
Dividend & Returns
AVITA Medical, Inc. (RCEL) had negative free cash flow of $30.7M in fiscal year 2025, likely due to heavy capital investments.